Financial Forecast Revision - The company revised its 2023 net profit forecast to approximately CNY 14,485,200, a decrease of 64.68% compared to the previous year's CNY 41,013,200[4] - The revision was due to increased provisions for expected credit losses on accounts receivable and contract assets, as well as adjustments to prepaid accounts over three years[5] - The performance period for the forecast is from January 1, 2023, to December 31, 2023[3] Risk Warning and Disclosure - The company has issued a risk warning regarding the financial data, advising investors to refer to the detailed annual report for accurate figures[8] - The board of directors has apologized for any inconvenience caused by the forecast revision and committed to improving information disclosure quality in the future[7]
春光药装(838810) - 2023 Q4 - 年度业绩预告(更正)